1-7 of 7
Sarah K. Knutson
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer

Robinson Triboulet, Khikmet Sadykov, Darren M. Harvey, David M. Wilson, Michael J. Steinbaugh, Christopher B. Mayo, Dillon Hawley, Andrew Madanjian, Corey Fyfe, Christina Bracken, Izarys Rivera-Rivera, Anna Ericsson, Andrew R. Snyder, Sarah K. Knutson, Ross L. Stein, Veronica Gibaja, Shomir Ghosh, Robert M. Campbell
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2024) 23 (12): 1779–1788.
https://doi.org/10.1158/1535-7163.MCT-24-0176
Published: 03 December 2024
View article titled, Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer
Open the PDF for Targeting the Synthetic Lethal Relationship between FOCAD and TUT7 Represents a Potential Therapeutic Opportunity for TUT4/7 Small-Molecule Inhibitors in Cancer in another window
Includes: Supplementary data
Journal Articles

EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL

Dorothy Brach, Danielle Johnston-Blackwell, Allison Drew, Trupti Lingaraj, Vinny Motwani, Natalie M. Warholic, Igor Feldman, Christopher Plescia, Jesse J. Smith, Robert A. Copeland, Heike Keilhack, Elayne Chan-Penebre, Sarah K. Knutson, Scott A. Ribich, Alejandra Raimondi, Michael J. Thomenius
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (11): 2586–2597.
https://doi.org/10.1158/1535-7163.MCT-16-0840
Published: 01 November 2017
View article titled, EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL
Open the PDF for EZH2 Inhibition by Tazemetostat Results in Altered Dependency on B-cell Activation Signaling in DLBCL in another window
Includes: Supplementary data
Journal Articles

Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: In Vitro and In Vivo Preclinical Models

Elayne Chan-Penebre, Kelli Armstrong, Allison Drew, Alexandra R. Grassian, Igor Feldman, Sarah K. Knutson, Kristy Kuplast-Barr, Maria Roche, John Campbell, Peter Ho, Robert A. Copeland, Richard Chesworth, Jesse J. Smith, Heike Keilhack, Scott A. Ribich
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2017) 16 (5): 850–860.
https://doi.org/10.1158/1535-7163.MCT-16-0678
Published: 02 May 2017
View article titled, Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <em>In Vitro</em> and <em>In Vivo</em> Preclinical Models
Open the PDF for Selective Killing of SMARCA2- and SMARCA4-deficient Small Cell Carcinoma of the Ovary, Hypercalcemic Type Cells by Inhibition of EZH2: <em>In Vitro</em> and <em>In Vivo</em> Preclinical Models in another window
Includes: Supplementary data
Journal Articles

Abstract C162: A medium-throughput single cell CRISPR-Cas9 assay to assess gene essentiality

Alexandra R. Grassian, Tim Scales, Sarah K. Knutson, Nicola J. McCarthy, Chris E. Lowe, Jon D. Moore, Robert A. Copeland, Heike Keilhack, Jesse J. Smith, Julie A. Wickendon, Scott Ribich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C162.
https://doi.org/10.1158/1535-7163.TARG-15-C162
Published: 01 December 2015
View article titled, Abstract C162: A medium-throughput single cell CRISPR-Cas9 assay to assess gene essentiality
Journal Articles

Abstract B85: EZH2 plays a critical role in B-cell maturation and in non-Hodgkin's lymphoma: Interplay between EZH2 function and B-cell activation

Danielle Johnston, Dorothy Brach, Christopher Plescia, Alison Drew, Trupti Lingaraj, Natalie Warholic, Jesse J. Smith, Robert A. Copeland, Heike Keilhack, Elayne Penebre, Sarah K. Knutson, Scott Ribich, Michael J. Thomenius, Alejandra Raimondi
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): B85.
https://doi.org/10.1158/1535-7163.TARG-15-B85
Published: 01 December 2015
View article titled, Abstract B85: EZH2 plays a critical role in B-cell maturation and in non-Hodgkin's lymphoma: Interplay between EZH2 function and B-cell activation
Journal Articles

Abstract C87: EZH2 inhibition leads to decreased proliferation in SMARCA4-deleted ovarian cancer cell lines

Sarah K. Knutson, Allison E. Drew, Christopher Plescia, Robert A. Copeland, Jesse J. Smith, Heike Keilhack, Scott Ribich
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2015) 14 (12_Supplement_2): C87.
https://doi.org/10.1158/1535-7163.TARG-15-C87
Published: 01 December 2015
View article titled, Abstract C87: EZH2 inhibition leads to decreased proliferation in SMARCA4-deleted ovarian cancer cell lines
Journal Articles

Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in EZH2-Mutant Non-Hodgkin Lymphoma

Sarah K. Knutson, Satoshi Kawano, Yukinori Minoshima, Natalie M. Warholic, Kuan-Chun Huang, Yonghong Xiao, Tadashi Kadowaki, Mai Uesugi, Galina Kuznetsov, Namita Kumar, Tim J. Wigle, Christine R. Klaus, Christina J. Allain, Alejandra Raimondi, Nigel J. Waters, Jesse J. Smith, Margaret Porter-Scott, Richard Chesworth, Mikel P. Moyer, Robert A. Copeland, Victoria M. Richon, Toshimitsu Uenaka, Roy M. Pollock, Kevin W. Kuntz, Akira Yokoi, Heike Keilhack
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (4): 842–854.
https://doi.org/10.1158/1535-7163.MCT-13-0773
Published: 06 April 2014
View article titled, Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <em>EZH2</em>-Mutant Non-Hodgkin Lymphoma
Open the PDF for Selective Inhibition of EZH2 by EPZ-6438 Leads to Potent Antitumor Activity in <em>EZH2</em>-Mutant Non-Hodgkin Lymphoma in another window
Includes: Supplementary data